S. Wroblewski

发表

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Brad J. Wood, M. Proschan, R. Dewar, 2013, JAMA.

Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues.

J. Kopeček, P. Kopec̆ková, M. Berenson, 2000, Journal of biomedical materials research.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2019, The Lancet.

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

J. Schellens, A. Huitema, R. Madan, 2019, Journal of pharmaceutical and biomedical analysis.

Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study.

W. Shi, P. Mudd, M. Aivado, 2010 .

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Y. Pommier, W. Figg, A. Huitema, 2020, Cancer Chemotherapy and Pharmacology.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2019, Blood.

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Andre H Crepaldi, M. Dimopoulos, A. Jakubowiak, 2021, BMC cancer.

The Influence of a Colonic Microbiota on HPMA Copolymer Lectin Conjugates Binding in Rodent Intestine

B. Říhová, J. Kopeček, P. Kopec̆ková, 2001, Journal of drug targeting.

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

G. Cook, S. Basu, R. Schots, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

M. Dimopoulos, A. Jakubowiak, Sung-Soo Yoon, 2018, Blood.

Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial.

J. San-Miguel, K. Gries, J. Fastenau, 2018 .

Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

A. Jakubowiak, S. Iida, Je-Jung Lee, 2018 .

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

E. Plimack, J. Schlom, E. Ross, 2022, Prostate Cancer and Prostatic Diseases.

Potential of lectin-N-(2-hydroxypropyl)methacrylamide copolymer-drug conjugates for the treatment of pre-cancerous conditions.

J. Kopeček, M. Berenson, S. Wroblewski, 2001, Journal of controlled release : official journal of the Controlled Release Society.